



Patient Name	: Baby Ivanna Agarwal	Centre	: 1104 - Max Smart- M S S S H
Age/Gender	: 4 Y 0 M 8 D /F	OP/IP No/UHID	: IP/145582/SC-SG-1307/
MaxID/Lab ID	: SKCT.567109/0833122304836	Collection Date/Time	e : 06/Dec/2023 11:28AM
Ref Doctor	: Dr.Bhaskar Saikia	Reporting Date/Time	e : 10/Dec/2023 03:02PM

	Outsourced			
Test Name	Result	Unit	Bio Ref Interval	
Diabeties Type -1, Auto Immune Pr	ofile (L)*			
GAD-65	>2000	IU/mL	< 10.0	
Anti IA-2	<1.00	IU/mL	< 10.0	
Insulin Antibodies	0.64	U/mL	< 12.00	
ZnT8 Antibodies	<10.0	U/mL	< 15	
Islet Cell Antibody	Negative			
TITER	1:10			

Comment Interpretation :-

RESULT of INSULIN ANTIBODIES IN U/mL	REMARKS
< 12	Normal
12 - 18	Equivocal
> 18	Positive

Comment

Type 1 Diabetes mellitus (insulin-dependent diabetes mellitus, IDDM) is the result of a T-cell mediated destruction of the beta cells in genetically predisposed individuals. Autoantibodies to a variety of islet cell antigens appear during the course of autoimmune insulitis. Type 1 Diabetes is characterised by the presence of distinct circulating autoantibodies including autoantibodies to glutamic acid decarboxylase (GAD), protein tyrosine phosphatase (IA2), insulin, and autoantibodies directed against cytoplasmic components of islet cells. Measurement of autoantibodies to GAD, IA2, insulin and of cytoplasmic islet cell antigens (ICA) has been shown to be of significant value for the diagnosis and prediction of type 1 diabetes in first-degree relatives of diabetic patients.

One or several of these autoantibodies are found in most new onset type 1 diabetic patients. They can also be detected before the onset of the disease and characterise the so-called prediabetic period.

These autoantibodies help to estimate the risk of an individual developing type 1 diabetes. Testing for all autoantibodies i.e. GAD-65, Anti- IA2, insulin antibodies & ICA is highly recommended for risk assessment of type 1 diabetes.

*** End Of Report ***

Kindly correlate with clinical findings

Dr. Poonam. S. Das, M.D. Principal Director-Max Lab & Blood Bank Services

me

Dr. Dilip Kumar M.D. Associate Director & Manager Quality

Dr. Nitin Dayal, M.D. Principal Consultant & Head, Haematopathology

Booking Centre :1104 - Max Smart- M S S S H, , The authenticity of the report can be verified by scanning the Q R Code on top of the page Page 1 of 1

Max Lab Limited (A Wholly Owned Subsidiary of Max Healthcare Institute Ltd.)

Max Super Speciality Hospital, Saket (West Block), 1, Press Enclave Road, Saket, New Delhi - 110 017, Phone: +91-11-6611 5050 (CIN No.: U85100DL2021PLC381826)

🕻 Helpline No. 7982 100 200 🛛 🌐 www.maxlab.co.in 🛛 🔤 feedback@maxlab.co.in

Conditions of Reporting: 1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient name as identified in the bill/test request form. 2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory. 3. The reported results are for the information and interpretation by the referring doctor only 4. Some tests are referred to other laboratories to provide a wider test menu to the customer. 5. Max Healthcare shall in no event be lable for accidental damages loss, or destruction of specimen which is not attributable to any direct and mala fide act or omission of Max Healthcare or its employees. Liability of Max Healthcare for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.